VivoPower PLC is engaged in building, owning, and leasing powered land and data center infrastructure for AI compute applications... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BYLD | 21.59 | 0.02 | +0.09% |
| iShares Yield Optimized Bond ETF (BYLD) | |||
| NVBU | 31.73 | N/A | N/A |
| AllianzIM U.S. Equity Buffer15 Uncapped Nov ETF (NVBU) | |||
| DECT | 40.92 | -0.05 | -0.12% |
| AllianzIM U.S. Equity Buffer10 Dec ETF (DECT) | |||
| TPRY | 18.83 | -0.16 | -0.83% |
| VistaShares Target 15 TEPRTantrum Contrarian Distribution ETF (TPRY) | |||
| EMOP | 50.57 | -0.47 | -0.92% |
| AB Emerging Markets Opportunities ETF (EMOP) | |||
A.I.dvisor indicates that over the last year, VIVO has been loosely correlated with INSP. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if VIVO jumps, then INSP could also see price increases.
| Ticker / NAME | Correlation To VIVO | 1D Price Change % | ||
|---|---|---|---|---|
| VIVO | 100% | -4.52% | ||
| INSP - VIVO | 41% Loosely correlated | +3.77% | ||
| ICLR - VIVO | 38% Loosely correlated | +0.14% | ||
| BRKR - VIVO | 37% Loosely correlated | -4.40% | ||
| OSPN - VIVO | 36% Loosely correlated | -2.03% | ||
| GMED - VIVO | 36% Loosely correlated | +2.13% | ||
More | ||||
| Ticker / NAME | Correlation To VIVO | 1D Price Change % |
|---|---|---|
| VIVO | 100% | -4.52% |
| diagnostics theme (19 stocks) | 13% Poorly correlated | -1.77% |
| biotechnology theme (202 stocks) | 11% Poorly correlated | -2.18% |
| Computer Communications theme (166 stocks) | 10% Poorly correlated | -1.21% |
| drugs theme (213 stocks) | 9% Poorly correlated | -2.15% |
| cancer theme (69 stocks) | 3% Poorly correlated | -1.52% |
a manufacturer of diagnostic products
Industry ComputerCommunications
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +6.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIVO advanced for three days, in 187 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
VIVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIVO as a result. In 74 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for VIVO turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
VIVO moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VIVO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. VIVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.716) is normal, around the industry mean (17.861). P/E Ratio (35.336) is within average values for comparable stocks, (159.605). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (104.490).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.